Cargando…

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women

Total hysterectomy and bilateral adnexectomy is the standard treatment for atypical endometrial hyperplasia and early-stage endometrial cancer. However, the recommended surgical treatment precludes future pregnancy when these conditions are diagnosed in women in their fertile age. In these patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Uccella, Stefano, Zorzato, Pier Carlo, Dababou, Susan, Bosco, Mariachiara, Torella, Marco, Braga, Andrea, Frigerio, Matteo, Gardella, Barbara, Cianci, Stefano, Laganà, Antonio Simone, Franchi, Massimo Piergiuseppe, Garzon, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504942/
https://www.ncbi.nlm.nih.gov/pubmed/36143933
http://dx.doi.org/10.3390/medicina58091256
_version_ 1784796346884030464
author Uccella, Stefano
Zorzato, Pier Carlo
Dababou, Susan
Bosco, Mariachiara
Torella, Marco
Braga, Andrea
Frigerio, Matteo
Gardella, Barbara
Cianci, Stefano
Laganà, Antonio Simone
Franchi, Massimo Piergiuseppe
Garzon, Simone
author_facet Uccella, Stefano
Zorzato, Pier Carlo
Dababou, Susan
Bosco, Mariachiara
Torella, Marco
Braga, Andrea
Frigerio, Matteo
Gardella, Barbara
Cianci, Stefano
Laganà, Antonio Simone
Franchi, Massimo Piergiuseppe
Garzon, Simone
author_sort Uccella, Stefano
collection PubMed
description Total hysterectomy and bilateral adnexectomy is the standard treatment for atypical endometrial hyperplasia and early-stage endometrial cancer. However, the recommended surgical treatment precludes future pregnancy when these conditions are diagnosed in women in their fertile age. In these patients, fertility-sparing treatment may be feasible if the desire for childbearing is consistent and specific conditions are present. This review summarizes the available evidence on fertility-sparing management for atypical endometrial hyperplasia and early-stage endometrial cancer. Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length. Intrauterine progestin therapy has proved a valid alternative option when oral progestins are not tolerated. GnRH analogs, metformin, and hysteroscopic resection in combination with progestins appear to increase the overall efficacy of the treatment. After a complete response, conception is recommended; alternatively, maintenance therapy with strict follow-up has been proposed to decrease recurrence. The risk of disease progression is not negligible, and clinicians should not overlook the risk of hereditary forms of the disease in young patients, in particular, Lynch syndrome. Hysterectomy is performed once the desire for childbearing desire has been established. The conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer is feasible, provided a strong desire for childbearing and permitting clinical–pathological conditions. However, patients must be aware of the need for a strict follow-up and the risk of progression with a possible consequent worsening of the prognosis. More homogenous and well-designed studies are necessary to standardize and identify the best treatment and follow-up protocols.
format Online
Article
Text
id pubmed-9504942
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95049422022-09-24 Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women Uccella, Stefano Zorzato, Pier Carlo Dababou, Susan Bosco, Mariachiara Torella, Marco Braga, Andrea Frigerio, Matteo Gardella, Barbara Cianci, Stefano Laganà, Antonio Simone Franchi, Massimo Piergiuseppe Garzon, Simone Medicina (Kaunas) Review Total hysterectomy and bilateral adnexectomy is the standard treatment for atypical endometrial hyperplasia and early-stage endometrial cancer. However, the recommended surgical treatment precludes future pregnancy when these conditions are diagnosed in women in their fertile age. In these patients, fertility-sparing treatment may be feasible if the desire for childbearing is consistent and specific conditions are present. This review summarizes the available evidence on fertility-sparing management for atypical endometrial hyperplasia and early-stage endometrial cancer. Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length. Intrauterine progestin therapy has proved a valid alternative option when oral progestins are not tolerated. GnRH analogs, metformin, and hysteroscopic resection in combination with progestins appear to increase the overall efficacy of the treatment. After a complete response, conception is recommended; alternatively, maintenance therapy with strict follow-up has been proposed to decrease recurrence. The risk of disease progression is not negligible, and clinicians should not overlook the risk of hereditary forms of the disease in young patients, in particular, Lynch syndrome. Hysterectomy is performed once the desire for childbearing desire has been established. The conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer is feasible, provided a strong desire for childbearing and permitting clinical–pathological conditions. However, patients must be aware of the need for a strict follow-up and the risk of progression with a possible consequent worsening of the prognosis. More homogenous and well-designed studies are necessary to standardize and identify the best treatment and follow-up protocols. MDPI 2022-09-11 /pmc/articles/PMC9504942/ /pubmed/36143933 http://dx.doi.org/10.3390/medicina58091256 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Uccella, Stefano
Zorzato, Pier Carlo
Dababou, Susan
Bosco, Mariachiara
Torella, Marco
Braga, Andrea
Frigerio, Matteo
Gardella, Barbara
Cianci, Stefano
Laganà, Antonio Simone
Franchi, Massimo Piergiuseppe
Garzon, Simone
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title_full Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title_fullStr Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title_full_unstemmed Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title_short Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
title_sort conservative management of atypical endometrial hyperplasia and early endometrial cancer in childbearing age women
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504942/
https://www.ncbi.nlm.nih.gov/pubmed/36143933
http://dx.doi.org/10.3390/medicina58091256
work_keys_str_mv AT uccellastefano conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT zorzatopiercarlo conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT dababoususan conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT boscomariachiara conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT torellamarco conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT bragaandrea conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT frigeriomatteo conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT gardellabarbara conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT ciancistefano conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT laganaantoniosimone conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT franchimassimopiergiuseppe conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen
AT garzonsimone conservativemanagementofatypicalendometrialhyperplasiaandearlyendometrialcancerinchildbearingagewomen